Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 92

1.

A three-gene signature as potential predictive biomarker for irinotecan sensitivity in gastric cancer.

Shen J, Wei J, Wang H, Yue G, Yu L, Yang Y, Xie L, Zou Z, Qian X, Ding Y, Guan W, Liu B.

J Transl Med. 2013 Mar 22;11:73. doi: 10.1186/1479-5876-11-73.

PMID:
23517622
[PubMed - in process]
Free PMC Article
2.

Synergistic anticancer effects of polyphyllin I and evodiamine on freshly-removed human gastric tumors.

Yue G, Wei J, Qian X, Yu L, Zou Z, Guan W, Wang H, Shen J, Liu B.

PLoS One. 2013 Jun 7;8(6):e65164. doi: 10.1371/journal.pone.0065164. Print 2013.

PMID:
23762305
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

SULF2 methylation is associated with in vitro cisplatin sensitivity and clinical efficacy for gastric cancer patients treated with a modified FOLFOX regimen.

Shen J, Wei J, Wang H, Yang Y, Yue G, Wang L, Yu L, Xie L, Sun X, Bian X, Zou Z, Qian X, Guan W, Liu B.

PLoS One. 2013 Oct 4;8(10):e75564. doi: 10.1371/journal.pone.0075564. eCollection 2013.

PMID:
24124496
[PubMed - indexed for MEDLINE]
Free PMC Article
4.

[Correlation between the methylation of SULF2 and WRN promoter and chemosensitivity to irinotecan in gastric cancer].

Wang L, Shen J, Meng LJ, Fan WF, Wang J, Liu BR.

Zhonghua Zhong Liu Za Zhi. 2013 Jun;35(6):418-22. Chinese.

PMID:
24119900
[PubMed - in process]
5.

Predictive biomarkers of chemotherapy efficacy in colorectal cancer: results from the UK MRC FOCUS trial.

Braun MS, Richman SD, Quirke P, Daly C, Adlard JW, Elliott F, Barrett JH, Selby P, Meade AM, Stephens RJ, Parmar MK, Seymour MT.

J Clin Oncol. 2008 Jun 1;26(16):2690-8. doi: 10.1200/JCO.2007.15.5580. Erratum in: J Clin Oncol. 2008 Sep 10;26(26):4363.

PMID:
18509181
[PubMed - indexed for MEDLINE]
Free Article
6.

[The mRNA expression of BRCA1, ERCC1, TUBB3, PRR13 genes and their relationship with clinical chemosensitivity in primary epithelial ovarian cancer].

Zhao D, Zhang W, Li XG, Wang XB, Li M, Li YF, Tian HM, Song PP, Liu J, Chang QY, Wu LY.

Zhonghua Zhong Liu Za Zhi. 2012 Mar;34(3):196-200. doi: 10.3760/cma.j.issn.0253-3766.2012.03.008. Chinese.

PMID:
22780973
[PubMed - indexed for MEDLINE]
7.

[Predicting clinical chemo-sensitivity of primary ovarian cancer using adenosine triphosphate-tumor chemosensitivity assay combined with detection of drug resistance genes].

Zhao D, Zhang W, Li XG, Wang XB, Zhang LF, Li M, Li YF, Tian HM, Song PP, Liu J, Chang QY, Wu LY.

Zhonghua Fu Chan Ke Za Zhi. 2011 Mar;46(3):193-8. Chinese.

PMID:
21575453
[PubMed - indexed for MEDLINE]
8.

ERCC1 and BRCA1 mRNA expression levels in metastatic malignant effusions is associated with chemosensitivity to cisplatin and/or docetaxel.

Wang L, Wei J, Qian X, Yin H, Zhao Y, Yu L, Wang T, Liu B.

BMC Cancer. 2008 Apr 11;8:97. doi: 10.1186/1471-2407-8-97.

PMID:
18402708
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Aprataxin tumor levels predict response of colorectal cancer patients to irinotecan-based treatment.

Dopeso H, Mateo-Lozano S, Elez E, Landolfi S, Ramos Pascual FJ, Hernández-Losa J, Mazzolini R, Rodrigues P, Bazzocco S, Carreras MJ, Espín E, Armengol M, Wilson AJ, Mariadason JM, Ramon Y Cajal S, Tabernero J, Schwartz S Jr, Arango D.

Clin Cancer Res. 2010 Apr 15;16(8):2375-82. doi: 10.1158/1078-0432.CCR-09-3275. Epub 2010 Apr 6.

PMID:
20371676
[PubMed - indexed for MEDLINE]
Free Article
10.

Breast cancer resistance protein (BCRP) and excision repair cross complement-1 (ERCC1) expression in esophageal cancers and response to cisplatin and irinotecan based chemotherapy.

Bharthuar A, Saif Ur Rehman S, Black JD, Levea C, Malhotra U, Mashtare TL, Iyer R.

J Gastrointest Oncol. 2014 Aug;5(4):253-8. doi: 10.3978/j.issn.2078-6891.2014.018.

PMID:
25083297
[PubMed]
Free PMC Article
11.

KRAS Testing for Anti-EGFR Therapy in Advanced Colorectal Cancer: An Evidence-Based and Economic Analysis.

Health Quality Ontario.

Ont Health Technol Assess Ser. 2010;10(25):1-49. Epub 2010 Dec 1.

PMID:
23074403
[PubMed]
Free PMC Article
12.

Identification of a 5-gene signature for clinical and prognostic prediction in gastric cancer patients upon microarray data.

Wang Z, Yan Z, Zhang B, Rao Z, Zhang Y, Liu J, Yu L, Zhao Y, Yang B, Wu T, Gao J.

Med Oncol. 2013;30(3):678. doi: 10.1007/s12032-013-0678-5. Epub 2013 Aug 3.

PMID:
23912700
[PubMed - indexed for MEDLINE]
13.

Thymidylate synthase mRNA levels in plasma and tumor as potential predictive biomarkers for raltitrexed sensitivity in gastric cancer.

Shen J, Wang H, Wei J, Yu L, Xie L, Qian X, Zou Z, Liu B, Guan W.

Int J Cancer. 2012 Sep 15;131(6):E938-45. doi: 10.1002/ijc.27530. Epub 2012 Apr 4.

PMID:
22422354
[PubMed - indexed for MEDLINE]
14.

A BRCA1 deficient-like signature is enriched in breast cancer brain metastases and predicts DNA damage-induced poly (ADP-ribose) polymerase inhibitor sensitivity.

McMullin RP, Wittner BS, Yang C, Denton-Schneider BR, Hicks D, Singavarapu R, Moulis S, Lee J, Akbari MR, Narod SA, Aldape KD, Steeg PS, Ramaswamy S, Sgroi DC.

Breast Cancer Res. 2014 Mar 14;16(2):R25. doi: 10.1186/bcr3625.

PMID:
24625110
[PubMed - in process]
Free PMC Article
15.

Genome-wide analysis of three-way interplay among gene expression, cancer cell invasion and anti-cancer compound sensitivity.

Hsu YC, Chen HY, Yuan S, Yu SL, Lin CH, Wu G, Yang PC, Li KC.

BMC Med. 2013 Apr 16;11:106. doi: 10.1186/1741-7015-11-106.

PMID:
23590835
[PubMed - indexed for MEDLINE]
Free PMC Article
16.

ERCC1 and thymidylate synthase mRNA levels predict survival for colorectal cancer patients receiving combination oxaliplatin and fluorouracil chemotherapy.

Shirota Y, Stoehlmacher J, Brabender J, Xiong YP, Uetake H, Danenberg KD, Groshen S, Tsao-Wei DD, Danenberg PV, Lenz HJ.

J Clin Oncol. 2001 Dec 1;19(23):4298-304.

PMID:
11731512
[PubMed - indexed for MEDLINE]
17.

miRNA signature associated with outcome of gastric cancer patients following chemotherapy.

Kim CH, Kim HK, Rettig RL, Kim J, Lee ET, Aprelikova O, Choi IJ, Munroe DJ, Green JE.

BMC Med Genomics. 2011 Nov 23;4:79. doi: 10.1186/1755-8794-4-79.

PMID:
22112324
[PubMed - indexed for MEDLINE]
Free PMC Article
19.

Gene expression and effects of orally active derivatives of fluoropyrimidine on gastric and colorectal cancer.

Arakawa S, Ozawa S, Kawase J, Oshima H, Nagata H, Atsuta K, Umemoto S.

Exp Ther Med. 2010 Mar;1(2):331-336. Epub 2010 Mar 1.

PMID:
22993546
[PubMed]
Free PMC Article
20.

ERCC1 and BRAC1 mRNA expression levels in the primary tumor could predict the effectiveness of the second-line cisplatin-based chemotherapy in pretreated patients with metastatic non-small cell lung cancer.

Papadaki C, Sfakianaki M, Ioannidis G, Lagoudaki E, Trypaki M, Tryfonidis K, Mavroudis D, Stathopoulos E, Georgoulias V, Souglakos J.

J Thorac Oncol. 2012 Apr;7(4):663-71. doi: 10.1097/JTO.0b013e318244bdd4.

PMID:
22425915
[PubMed - indexed for MEDLINE]

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk